Lipid Abnormalities in Patient With Chronic Kidney Disease: A Cross-Sectional Study
Keywords:
lipid, CKDAbstract
ABSTRACT
Introduction: Chronic Kidney disease(CKD) is a public health problem with an increasing incidence and prevalence, poor outcome and high cost.Renal disease, in early as well as advanced stages, is associated with abnormalities in lipoprotein metabolism. Dyslipidemia appears to be independently associated with increased progression rate of CKD in patients with kidney disease and with increased risk of graft loss after renaltransplantation. This study was conducted to study the lipid abnormalities in CKD patients.
Methodology: Ahospital-based, observational, cross-sectional study was conducted among 89 patients attending Outpatient Department (OPD) and admitted in the ward ofBir Hospital with the diagnosis of CKD. Data was collected using the structured performa. Data was analyzed using SPSS version 16. Descriptive statistics (Frequency, men and percentage) and inferential statistics (Chi-square test) was used.
Results:Out of 89 patients, 63 had low and 26 had normal High Density Lipoprotein (HDL) which was statically significant with p value of 0.067. Low Density Lipoprotein (LDL) level of 30 patients out of 89 had optimal LDL, 12 out of 89 had near optimal LDL, 12had borderline high level of LDL, 26 out of 89 had high LDL level and 9 out of 89 had very high LDL.This elevation was statistically significant.Out of 89 patients 21 had normal, 19 had borderline high and 49 had high TG which was statically significant.Out of 89, 41 had desirable , 12 had borderline high and 36 had high total cholesterol which was statically significant.
Conclusion: Hypertriglyceridemia and low HDL are the common lipid abnormalities in CKD patients. However LDL and total cholesterol were also increased.
References
Levey A, Eckardt K, Tsukamoto Y, Levin A, Coresh J, Rossert J et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International. 2005;67(6):2089-2100. https://doi.org/10.1111/j.1523-1755.2005.00365.x [Pubmed]
National Institute of Health, National Heart, Lung and Blood Institute, National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report [internet].2002 Sep, No. 02-5215. [Google Schoolar]
Samuelsson O, Attman P, Knight GC, Larrson R, Mulec H, Weiss L, et al. Complex apolipoprotein B-containing lipoprotein particles are associated with higher rate of progression of human chronic renal insufficiency. Jam SocNephrol. 1998;9(8):1482-1488. https://doi.org/10.1681/ASN.V981482 [Google]
Cusick M, Chew E, Hoogwerf B, Agrón E, Wu L, Lindley A et al. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney International. 2004;66(3):1173-1179. https://doi.org/10.1111/j.1523-1755.2004.00869.x [Google Scholar]
Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase inhibition in uremia: Identification of pre-β-HDL as a major inhibitor in normal and uremic plasma. Kidney international. 1996 May 1;49(5):1360-71.[Google Schoolar]
Stefanovic V, Milojkovic M. Treatment of dyslipidemia in chronic kidney disease: Int J Artif Organs. 2004:821–27. doi: 10.1177/039139880402701002. [Pubmed]
Poudel B, Yadav BK, Jha B. Dyslipidaemia in chronic kidney disease in Nepalese population. Mymensingh Med J 2013; 22(1):157-63. [Google Schoolar] [Pubmed]
Crook ED, Thallpureddy A, Stephen M. Lipid abnormalities and renal disease.am j med sci 2003; 325:340-48. Doi: https://doi.org/10.1097/00000441-200306000-00005 [Google Schoolar]
ATP III Guidelines At-a-Glance - Provider Resource Center. https://prc.hmsa.com/s/article/ATP-III-Guidelines-At-a-Glance. [Google]
Rutkowski M, Mann W, Derose S, Selevan D, Pascual N, Diesto J, Crooks P. Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente. American journal of kidney diseases. 2009 Mar 1;53(3):S86-99. doi: https://doi.org/10.1053/j.ajkd.2008.07.052 [Google Schoolar]
Bauer C, Melamed ML, Hostetter TH. Staging of chronic kidney disease: time for a course correction. J Am Soc Nephrol. 2008; 19 (5): 844-46. doi:10.1681/ASN.2008010110{pubmed}
Shah B, Nair S, Sirsat RA, Ashavaid T F, Nair K. Dyslipidemia in patients with chronic renal Failure and in renal transplant patients: J postgrad Med 1994; 40:57-60. https://pubmed.ncbi.nlm.nih.gov/8737552/ [Pubmed]]
Bargman JM, Skorecki K. Chronic Kidney Disease chap 280.In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J (eds). Harrison's Principle of Internal Medicine, 18th ed. New York: McGraw-Hill; 2012. p.2310.
Vaziri N D. Dyslipidemia of chronic renal failure: the nature, mechanisms,and potential consequences. Am J Physiol Renal Physiol 290: F262–F272, 2006; doi:10.1152/ajprenal.00099.2005
Mikolasevic I, Žutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. International Journal of Nephrology and Renovascular Disease 2017:10 35–45. https://pubmed.ncbi.nlm.nih.gov/28223836/
Ravichandran R R, Nerurkar S V, Acharya V N, Taskar S P. Hyperlipidemia in patients with Chronic renal failure. J Postgrad med. 1983.29:212. https://www.jpgmonline.com/text.asp?1983/29/4/212/5510
Mouhamed DH, Ezzaher A, Neffati F, Gaha L, Douki W, Najjar MF. Association between cigarette smoking and dyslipidemia. Immuno-analyse & Biologie Spécialisée. 2013 Aug 1; 28 (4):195-200. https://doi.org/10.1016/j.immbio.2013.03.004 [Google Scholar]
Tan X J, Jiao G P, Y.J. Ren, X.R. Gao, Y. Ding, X.R. Wang, and H. Xu Relationship Between Smoking and Dyslipidemia in Western Chinese Elderly Males. Journal of Clinical Laboratory Analysis. 2008. 22: 159–63. DOI 10.1002/jcla.20235
Idemudia JO, Idogun HF. Effect of age and gender on lipid profile in healthy rural population of Edo State, Nigeria. Tropical Journal of Health Sciences. 2017 Jul 31;24(3):41-4.{google scholar}
Sharma A, Khadka S, Amgain K, Acharya S, Panta PP. Rationale of α-Ketoanalogue Supplemented with Low Protein Diet for the Treatment of Chronic Kidney Disease. Journal of Karnali Academy of Health Sciences. 2020;3(3). [Google Scholar]
Dhital M, Paudel DP, Amgain K. Thyroid Dysfunction and Risk to Coronary Heart Disease Based on Serum Cholesterol Level: A Laboratory Based study in Kathmandu, Nepal 12. Asian Journal of Biological and Life Sciences. 2014;3(1). [Google Scholar] [Full Text]
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Rajendra Mani Giri, Manen Prasad Gorkhaly
This work is licensed under a Creative Commons Attribution 4.0 International License.
The author(s) retain the copyright and the full publishing right without restriction under the Creative Commons Attribution 4.0 International License (CC BY 4.0) which allows readers to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, even commercially, provided the work is properly attributed. (https://creativecommons.org/licenses/by/4.0/).
Author(s) grant the non-exclusive publishing right to the Journal of Karnali Academy of Health Sciences (JKAHS). The publishing rights include the rights to publish, reproduce, distribute, include in indexes or search databases or other media in print or online. The JKAHS may require revisions to the manuscript before acceptance for publication or may choose not to publish it based on the judgement of the editors. Further, JKAHS might retract, withdraw, or publish a correction or other notice after publication, if such publication would be inconsistent with the good publication practices and associated guidelines set forth by the COPE (Committee on Publication Ethics) (https://publicationethics.org/core-practices).
More information about the Creative Commons Attribution 4.0 International License can be found in the webpage of Creative Commons (CC) by following the link provided below: https://creativecommons.org/licenses/by/4.0/
